Clarity Pharmaceuticals progresses SECURE trial to multi-dose phase

Clarity Pharmaceuticals (ASX: $CU6) has successfully completed cohort 3 of the SECURE trial, advancing to cohort 4, the first multi-dose phase. The trial investigates the safety and efficacy of 67Cu-SAR-bisPSMA for the treatment of metastatic castrate-resistant prostate cancer.

Executive Commentary on SECURE Trial Progression

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, expressed excitement about the progress of the SAR-bisPSMA programs, highlighting the remarkable responses observed in patients who had previously undergone multiple lines of therapy. He emphasized the favorable safety profile and the promising PSA reductions, especially in cohorts 2 and 3, indicating the potential for 67Cu-SAR-bisPSMA to become the gold standard therapeutic agent for mCRPC patients once approved.

Summary of SECURE Trial Advancement

Clarity Pharmaceuticals has successfully completed cohort 3 of the SECURE trial, with no dose limiting toxicities reported. The Safety Review Committee has recommended the progression to cohort 4, the first multi-dose phase, at the highest dose level investigated in the study. Preliminary data shows promising PSA reductions and a favorable safety profile, supporting the potential for 67Cu-SAR-bisPSMA to become a leading therapeutic agent for metastatic castrate-resistant prostate cancer.